Imstar-Dx's team is pleased to announce its participation in the next United States and Canadian Academy of Pathology (USCAP) 2023 Annual Meeting. New Data will be communicated in a poster titled: “Digital Image Analysis-Aided Assessment of HER2 ...
IMSTAR Dx will present an oral communication on November 16th, 2022, at 2 pm in room 241, during the Breast Pathology and Artificial Intelligence session under the title of : Automated evaluation of Ki67 and HER2 markers in breast cancer and Ki6 ...
IMSTAR Dx est de retour en tant qu'intervenant pour une nouvelle édition de Carrefour Pathologie, tenue à Paris du 16 au 18 Novembre prochains. Notre présentation a pour titre « Evaluation automatisée des marqueurs Ki67 et HER2 ...
On October 13th, 2022, IMSTAR will be present at the meeting organized by the Francophone Group of Cytogenetics Hematology (GFCH), affiliated to the French Society of Hematology (SFH) and the French Federation of Human Genetics (FFGH), in person, at ...
IMSTAR participated in the Computational Pathology Symposium, September 4, 2022. The program of this particularly rich symposium, made it possible to convey a faithful and complete global image of the reality of the field. Speakers from Nordic co ...
Retour sur notre participation aux 𝟒𝟓𝐞𝐬 𝐀𝐬𝐬𝐢𝐬𝐞𝐬 𝐝𝐞 𝐏𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐢𝐞 𝐝𝐞 𝐒𝐭𝐫𝐚𝐬𝐛𝐨𝐮𝐫𝐠 les 19 et 20 Mai derniers avec Françoise Soussaline, Mélissande Cossutta et Caroline Egele devant notre poster sous le titre de : 𝐀𝐩𝐩𝐨𝐫𝐭𝐬 𝐝𝐞 𝐥’ ...
Venez nous rencontrer aux 45ème Assises de Pathologie, 19-20 Mai 22, Strasbourg Jeudi 19 mai à 15h20 Le Pr Jean-Pierre Bellocq, Président de l'Association Française d'Assurance Qualité (AFAQAP) partagera son expérience des tests d'aptitude int ...
AfAQap, for French Association for Quality Assurance in Pathological Anatomy and Cytology (PAC) in English, is the organization that allows pathologists to regularly evaluate and improve the quality of their practices in the fields of diagnosis, tec ...
President Emmanuel Macron's speech on World Cancer Day organized by the National Cancer Institute (INCa) on February 4th confirms more than ever the need for early cancer detection.Imstar-Dx has been engaged in this struggle for more than 25 ye ...
IMSTAR received a Seal of Excellence from the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020, for its project CECAD: A novel Blood test by Cell imaging for Ea ...
IA-based Solutions Quantitative Digital Pathology
Over 25 years of experience in Intelligent Software solutions, Imstar-Dx is a Spin-off of the CEA’s Nuclear Medicine Department, Life Sciences Division. Imstar-Dx is focused on cancer research and diagnosis since its inception.
© 2021 IMSTAR DX BUSINESS THEME.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
